Ligand Pharmaceuticals (LGNDZ) Intangibles (2016 - 2025)
Ligand Pharmaceuticals (LGNDZ) has disclosed Intangibles for 16 consecutive years, with $225.4 million as the latest value for Q4 2025.
- Quarterly Intangibles fell 15.45% to $225.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $225.4 million through Dec 2025, down 15.45% year-over-year, with the annual reading at $225.4 million for FY2025, 15.45% down from the prior year.
- Intangibles hit $225.4 million in Q4 2025 for Ligand Pharmaceuticals, down from $233.5 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $583.8 million in Q1 2021 to a low of $225.4 million in Q4 2025.
- Historically, Intangibles has averaged $369.0 million across 5 years, with a median of $320.1 million in 2023.
- Biggest five-year swings in Intangibles: skyrocketed 182.68% in 2021 and later crashed 39.1% in 2023.
- Year by year, Intangibles stood at $376.7 million in 2021, then dropped by 9.09% to $342.5 million in 2022, then dropped by 12.51% to $299.6 million in 2023, then dropped by 11.0% to $266.6 million in 2024, then decreased by 15.45% to $225.4 million in 2025.
- Business Quant data shows Intangibles for LGNDZ at $225.4 million in Q4 2025, $233.5 million in Q3 2025, and $250.1 million in Q2 2025.